NeoGenomics, Inc. Stock

Equities

NEO

US64049M2098

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-07-19 pm EDT 5-day change 1st Jan Change
14.51 USD -1.56% Intraday chart for NeoGenomics, Inc. -1.89% -10.32%
Sales 2024 * 656M Sales 2025 * 719M Capitalization 1.85B
Net income 2024 * -72M Net income 2025 * -47M EV / Sales 2024 * 3.23 x
Net Debt 2024 * 265M Net Debt 2025 * 238M EV / Sales 2025 * 2.91 x
P/E ratio 2024 *
-25.5 x
P/E ratio 2025 *
-40.2 x
Employees 2,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.75%
More Fundamentals * Estimated data
Dynamic Chart
1 day-1.56%
1 week-1.89%
Current month+4.61%
1 month+11.53%
3 months+7.24%
6 months-7.76%
Current year-10.32%
More quotes
1 week
14.48
Extreme 14.48
15.98
1 month
12.93
Extreme 12.93
15.98
Current year
12.78
Extreme 12.775
17.49
1 year
11.03
Extreme 11.03
21.22
3 years
6.00
Extreme 6
54.74
5 years
6.00
Extreme 6
61.57
10 years
3.33
Extreme 3.33
61.57
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 22-08-14
Chairman 61 15-06-11
Director of Finance/CFO 58 22-12-06
Members of the board TitleAgeSince
Director/Board Member 67 20-07-14
Chief Executive Officer 61 22-08-14
Director/Board Member 63 22-11-02
More insiders
Date Price Change Volume
24-07-19 14.51 -1.56% 625,199
24-07-18 14.74 -4.90% 588,657
24-07-17 15.5 -2.15% 646,209
24-07-16 15.84 +6.81% 1,006,449
24-07-15 14.83 +0.27% 654,194

Delayed Quote Nasdaq, July 19, 2024 at 04:00 pm EDT

More quotes
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
14.51 USD
Average target price
20.36 USD
Spread / Average Target
+40.34%
Consensus